{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:09:59Z","timestamp":1761743399274},"reference-count":47,"publisher":"SLACK, Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:sec>\n            <jats:title>Background and Objective:<\/jats:title>\n            <jats:p>To evaluate early retinal, choroidal, and scleral abnormalities induced by a hypercholesterolemic diet and the prevention of these abnormalities after oral administration of rosiglitazone in rabbits.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>Fifty-four New Zealand rabbits were divided into four study groups: control group, normal diet; group 1, hypercholesterolemic diet; group 2, hypercholesterolemic diet associated with daily administration of 3 mg of rosiglitazone from day 14 after beginning the diet; and group 3, hypercholesterolemic diet associated with daily administration of 3 mg of rosiglitazone since the beginning of the experiment. Sclera and choroid underwent histologic and histomorphometric analyses. Retina underwent immunohistochemical analysis with anti-calretinin and anti-glial fibrillary acidic protein (GFAP) antibodies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n              No abnormalities were observed in the control group. Group 1 had significant increases in scleral and choroidal thicknesses compared with the control group (\n              <jats:italic>P<\/jats:italic>\n              &lt; .01) and group 3 (\n              <jats:italic>P<\/jats:italic>\n              &lt; .05). Group 1 presented significant increases in immunoreactivity (\n              <jats:italic>P<\/jats:italic>\n              &lt; .001) to the anti-calretinin antibody compared with the other groups. Groups 2 and 3 had significant (\n              <jats:italic>P<\/jats:italic>\n              &lt; .002) increases in calretinin immunoreactivity compared with the control group. GFAP was negative in all groups.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The hypercholesterolemic diet induced early retinal, choroidal, and scleral abnormalities. Rosiglitazone preserved the structural anatomy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/15428877-20100726-05","type":"journal-article","created":{"date-parts":[[2010,8,26]],"date-time":"2010-08-26T20:55:06Z","timestamp":1282856106000},"page":"562-571","source":"Crossref","is-referenced-by-count":3,"title":["Sclerochorioretinal Abnormalities in Hypercholesterolemic Rabbits Treated with Rosiglitazone"],"prefix":"10.3928","volume":"41","author":[{"given":"Rogil Jos\u00e9","family":"de Almeida Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Muccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maur\u00edcio","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"Luchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rcia","family":"Olandoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel Eid","family":"Farah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalton Bertolin","family":"Pr\u00e9coma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(03)00030-4"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.09.033"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1076\/0271-3683(200001)2011-HFT008"},{"key":"e_1_3_1_5_2","first-page":"1891","article-title":"Effects of cholesterol and apolipoprotein E on retinal abnormalities in ApoE-deficient mice","volume":"42","author":"Ong JM","year":"2001","unstructured":"Ong JM, Zorapapel NC, Rich KA, et al. Effects of cholesterol and apolipoprotein E on retinal abnormalities in ApoE-deficient mice. Invest Ophthalmol Vis Sci. 2001;42:1891\u20131900.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2005.12.020"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2006.07.023"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2006.10.012"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0042-6989(97)00047-3"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(96)00095-X"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2004.11.018"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.093856"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.10.027"},{"key":"e_1_3_1_14_2","first-page":"2309","article-title":"Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization","volume":"41","author":"Murata T","year":"2000","unstructured":"Murata T, He S, Hangai M, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:2309\u20132317.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.13.3.215"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041001"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.9.2094"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.3.235"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10052"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.3132\/dvdr.2006.016"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.02.004"},{"key":"e_1_3_1_22_2","first-page":"119","article-title":"Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization","volume":"8","author":"Grossniklaus HE","year":"2002","unstructured":"Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8:119\u2013126.","journal-title":"Mol Vis"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0097"},{"key":"e_1_3_1_24_2","first-page":"2194","article-title":"Matrix metalloproteinases and metalloproteinases inhibitors in choroidal neovascular membranes","volume":"39","author":"Steen B","year":"1998","unstructured":"Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinases inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1998;39:2194\u20132200.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0393com"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-1246"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1373.2000.22416.x"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000097003.49585.5E"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2003.12.027"},{"key":"e_1_3_1_30_2","first-page":"2857","article-title":"Morphometric analysis of Bruch\u2019s membrane, the choriocapillaris, and the choroid in aging","volume":"35","author":"Ramrattan RS","year":"1994","unstructured":"Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PGH, de Jong PTVM. Morphometric analysis of Bruch\u2019s membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35:2857\u20132864.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00643-7"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70906-7"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000307448"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30974-8"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(89)32936-8"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27492009000100014"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.20.2411"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/83348"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.19.2097"},{"key":"e_1_3_1_40_2","first-page":"152","article-title":"Evaluation of early chorioretinal abnormalities in hypercholesterolemic rabbits submitted to the peroxisome proliferator-activated (PPAR)\u2013gamma agonist treatment (rosiglitazone): histological and histomorphometric study","volume":"8","author":"Torres RJA","year":"2009","unstructured":"Torres RJA, Maia M, Muccioli C, et al. Evaluation of early chorioretinal abnormalities in hypercholesterolemic rabbits submitted to the peroxisome proliferator-activated (PPAR)\u2013gamma agonist treatment (rosiglitazone): histological and histomorphometric study. Vision Pan-America. 2009;8:152\u2013154.","journal-title":"Vision Pan-America"},{"key":"e_1_3_1_41_2","first-page":"173","article-title":"Calretinin: sensor or buffer\u2013function still unclear","volume":"51","author":"Biling-Marczak K","year":"1999","unstructured":"Biling-Marczak K, Kuznicki J. Calretinin: sensor or buffer\u2013function still unclear. Pol J Pharmacol. 1999;51:173\u2013178.","journal-title":"Pol J Pharmacol"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6989(95)00322-3"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.7.3250"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/34178"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.54.101601.152409"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)00405-8"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1959.00940090221004"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2004.08.015"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.slackinc.com\/doi\/resolver.asp?doi=10.3928\/15428877-20100726-05","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T16:18:05Z","timestamp":1683044285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/15428877-20100726-05"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.3928\/15428877-20100726-05"],"URL":"https:\/\/doi.org\/10.3928\/15428877-20100726-05","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}